Glucotrack, Inc. Announces Results of Special Shareholder Meeting: Key Decisions and Potential Market Impact

Summary of the Special Meeting

Glucotrack, Inc. (NASDAQ: GCTK), a medical device company focused on non-invasive glucose monitoring solutions, held a special meeting of stockholders on March 12, 2026. The meeting was pivotal, with shareholders voting on several proposals that could significantly affect the company’s capital structure and future trajectory.

Key Proposals and Voting Results

• Nasdaq Stock Issuance (ELOC) Proposal:
  
  Shareholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of Common Stock to Sixth Borough Capital Fund, LP (“Sixth Borough”) pursuant to a purchase agreement dated September 11, 2025. The issuance could represent more than 20% of the company’s outstanding common stock, a threshold that often signals significant dilution and is closely watched by investors.
  
  Voting Results: 18,261 votes in favor, 7,846 votes against, and 293,631 broker non-votes.
• Nasdaq Stock Issuance (Warrants) Proposal:
  
  Shareholders approved the full issuance of shares of Common Stock upon exercise of 2,067,182 common warrants issued to investors in a private placement closed on December 31, 2025. This was in compliance with Nasdaq Listing Rule 5635(d), which governs large equity issuances.
  
  Voting Results: 26,134 votes in favor, 18,151 votes against, 7,841 broker non-votes, and 100,591 excluded shares (pre-funded warrants exercised before record date, not entitled to vote).
• Auditor Ratification Proposal:
  
  Shareholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the year ended December 31, 2025.
• Adjournment Proposal:
  
  This proposal was not presented as the previous three proposals received sufficient favorable votes to be adopted.

Important Shareholder Information & Potential Price-Sensitive Details

• Significant Dilution Risk: The approval of the ELOC and Warrants proposals means Glucotrack may issue shares exceeding 20% of its current outstanding stock. This could lead to substantial dilution for existing shareholders, which is typically a price-sensitive event and may affect share value.
• Strategic Capital Raising: The arrangements with Sixth Borough Capital Fund, LP and the private placement investors provide the company with critical capital, potentially facilitating growth initiatives, R&D, or operational expansion. However, the method (large share issuance and warrants) may affect investor sentiment regarding future earnings per share.
• Compliance with Nasdaq Rules: The company’s adherence to Nasdaq Listing Rule 5635(d) ensures regulatory compliance, which is necessary to maintain its NASDAQ listing and investor confidence.
• No Emerging Growth Company Status: Glucotrack, Inc. does not qualify as an emerging growth company, which may influence its regulatory requirements and disclosure obligations.
• Excluded Shares: Shares issued upon exercise of pre-funded warrants before the record date were not entitled to vote, indicating attention to compliance and shareholder fairness.

Trading Details

• Common Stock: Par value \$0.001 per share
• Trading Symbol: GCTK
• Exchange: The Nasdaq Stock Market LLC
• Shares Outstanding (as of record date): 1,011,279 shares of common stock

Potential Market Impact

The approval of large share issuances and warrant exercises could have a significant effect on Glucotrack’s share price in the near term. Investors should monitor trading activity closely, as dilution may lead to downward pressure on the stock, though the infusion of capital could also support operational growth and future profitability if managed effectively.

Company Background

Glucotrack, Inc. was formerly known as GlucoTrack, Inc. (name change in March 2022) and Integrity Applications, Inc. (name change in December 2010). The company is headquartered in Rutherford, NJ.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. The information presented is based on the company’s SEC filings and may be subject to change.

View Glucotrack, Inc. Historical chart here